Paul Thevenot
Overview
Explore the profile of Paul Thevenot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandow T, Gimenez J, Fowers K, Thevenot P
J Vasc Interv Radiol
. 2024 Sep;
35(12):1874-1875.
PMID: 39260795
No abstract available.
2.
Nunez K, Schneider M, Sandow T, Gimenez J, Hibino M, Fort D, et al.
Gastro Hep Adv
. 2024 Aug;
3(3):316-325.
PMID: 39131145
Background And Aims: Assessing aggressive biology at early-stage hepatocellular carcinoma (HCC) diagnosis remains challenging. Alpha-fetoprotein (AFP) is the only clinical biomarker of aggressive HCC. In this study, AFP, agglutinin-reactive AFP...
3.
Nunez K, Sandow T, Gimenez J, Hibino M, Cohen A, Thevenot P
Cancer Res Commun
. 2024 Jul;
4(8):2163-2173.
PMID: 39069671
Significance: 90Y can safely treat HCC; however, it causes transient lymphopenia. In this article, 90Y stimulates a peripheral effector memory response independent of initial treatment response. TCR sequencing revealed that...
4.
Sandow T, Gimenez J, Nunez K, Tramel R, Gilbert P, Oliver B, et al.
J Vasc Interv Radiol
. 2024 Jul;
35(11):1602-1612.e1.
PMID: 39047936
Purpose: To utilize voxel-based dosimetry following radiation segmentectomy (RS) to understand microsphere distribution and validate current literature regarding radiologic and pathologic outcomes. Materials And Methods: A retrospective, single-center analysis of...
5.
Koksal A, Ekmen N, Aydin Y, Nunez K, Sandow T, Delk M, et al.
J Hepatocell Carcinoma
. 2023 Nov;
10:1935-1954.
PMID: 37936599
Introduction: Extracellular vesicles could serve as a non-invasive biomarker for early cancer detection. However, limited methods to quantitate cancer-derived vesicles in the native state remain a significant barrier to clinical...
6.
Aydin Y, Koksal A, Thevenot P, Nunez K, Elgamal M, Koksal U, et al.
Eur J Gastroenterol Hepatol
. 2023 Aug;
35(10):1224-1229.
PMID: 37577793
Background And Aims: Tumor-directed therapies (TDTs) are a constitutive part of hepatocellular carcinoma (HCC) treatment in patients awaiting liver transplantation (LT). While most patients benefit from TDTs as a bridge...
7.
Koksal A, Thevenot P, Aydin Y, Nunez K, Sandow T, Widmer K, et al.
J Hepatocell Carcinoma
. 2022 Sep;
9:959-972.
PMID: 36105695
Background And Aim: HCC development in liver cirrhosis is associated with impaired autophagy leading to increased production of extracellular vesicles (EVs) including exosomes and microvesicles. The goal of the study...
8.
Gomez-Torres O, Amatya S, Kamberov L, Dhaibar H, Khanna P, Rom O, et al.
Am J Physiol Gastrointest Liver Physiol
. 2022 Jul;
323(3):G177-G187.
PMID: 35853010
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disease in the United States and worldwide. Nonalcoholic steatohepatitis (NASH), the most advanced form of...
9.
Nunez K, Sandow T, Patel J, Hibino M, Fort D, Cohen A, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406456
Due to active hepatocellular carcinoma (HCC) surveillance, many patients are diagnosed with early-stage disease and are usually amendable to curative treatments. These patients lack poor prognostic factors associated with Milan...
10.
Aydin Y, Koksal A, Thevenot P, Chava S, Heidari Z, Lin D, et al.
J Hepatocell Carcinoma
. 2021 Dec;
8:1579-1596.
PMID: 34917553
Background And Aims: Hepatocellular carcinoma (HCC) developing in the context of preexisting cirrhosis is characterized by impaired autophagy that results in increased exosome release. This study was conducted to determine...